CHRISTOPHER R. BLAGG, M.D.; BELDING H. SCRIBNER, M.D.
This content is PDF only. Please click on the PDF icon to access.
In the 20 years since dialysis for end-stage renal disease became possible, there has been a continuous change in the treated patient population, mainly as a result of increasing availability of funding for dialysis and transplantation. The paper by Cestero and colleagues (1) in this issue documents these changes in the experience of a regional end-stage renal disease treatment program. Changes include the increasing number of new patients presenting each year, the increasing average age of new patients, and the increasing number of patients with serious complications. The effects of these changes include a drop in the use of home
BLAGG CR, SCRIBNER BH. Medicare End-Stage Renal Disease Program: More Than a Billion Dollar Question. Ann Intern Med. ;93:501–502. doi: 10.7326/0003-4819-93-3-501
Download citation file:
Published: Ann Intern Med. 1980;93(3):501-502.
Chronic Kidney Disease, Healthcare Delivery and Policy, Nephrology.
Results provided by:
Copyright © 2019 American College of Physicians. All Rights Reserved.
Print ISSN: 0003-4819 | Online ISSN: 1539-3704
Conditions of Use